Platelet Cyclic Adenosine Monophosphate Phosphodiesterases: Targets for Regulating Platelet-Related Thrombosis

Platelets contain two cyclic adenosine monophosphate (cAMP) phosphodiesterases (PDEs) that regulate the level of cAMP, the major inhibitor of platelet activation pathways. PDE3A hydrolyzes cAMP to 5′ AMP with a low K_m. PDE3A is inhibited by cyclic guanosine monophosphate (cGMP), which provides a feedback control and controls basal levels of cAMP. In contrast, PDE2A hydrolyzes both cAMP and cGMP with a high K_m, is allosterically stimulated by cGMP at moderate levels, and may control the stimulated levels of cAMP. Using affinity labeling, chemical modification, and site-directed mutagenesis of highly conserved amino acids, the amino acids required for catalytic activity and/or metal binding are H752 and H756. The singular binding sites for cAMP include N845, E971, and F972, whereas the unique amino acids interacting with cGMP are Y751, H836, H849, and D950. Residues E866 and F1004 are present in both the overlapping cGMP and cAMP sites. Two inhibitors of PDE3A are used in clinical medicine: milrinone and cilostazol. Three amino acids, Y751, D950, and F1004, show decreased sensitivity to both inhibitors (increased K_i). These inhibitors mimic cGMP as an inhibitor of PDE3A rather than compete for cAMP binding. New nonhydrolyzable affinity labels inactivate PDE3A and are protected by Sp-cAMPS, a nonhydrolyzable substrate of the enzyme. These compounds have the potential to identify amino acids that are unique for PDE3A. An inhibitor of platelet PDE2A increases cAMP more than inhibitors of PDE3A but has much less effect on platelet activation, suggesting that these enzymes are present in different compartments of the cell.

KEYWORDS

cAMP - cGMP - cyclic nucleotide phosphodiesterases - antithrombotic therapy

REFERENCES

1 The GAF acronym comes from the names of the first three classes of proteins identified to contain them: cGMP-specific and regulated cyclic nucleotide phosphodieterol, Adenylcyclase and E. Coli transcription factor FhFA.

• 1 Salzman E W, Weisenberger H. Role of cyclic AMP in platelet function.  Adv Cyclic Nucleotide Res. 1972;  1 231-247
• 2 Simonds W F, Goldsmith P K, Codina J, Unson C G, Spiegel A M. Gi2 mediates α2-adrenergic inhibition of adenylyl cyclase in platelet membranes: In situ identification with Gα C-terminal antibodies.  Proc Natl Acad Sci USA. 1989;  86 7809-7813
• 3 Siegl A M, Daly J W, Smith J B. Inhibition of aggregation and stimulation of cyclic AMP generation in intact human platelets by the diterpene forskolin.  Mol Pharmacol. 1982;  21 680-687
• 4 Tani T, Sakurai K, Kimura Y, Ishikawa T, Hidaka H. Pharmacological manipulation of tissue cyclic AMP by inhibitors. Effects of phosphodiesterase inhibitors on the functions of platelets and vascular endothelial cells.  Adv Second Messenger Phosphoprotein Res. 1992;  25 215-227
• 5 Soderling S H, Beavo J A. Regulation of cAMP and cGMP signaling: new phosphodiesterases and new functions.  Curr Opin Cell Biol. 2000;  12 174-179
• 6 Hidaka H, Asano T. Human blood platelet 3′:5′-cyclic nucleotide phosphodiesterase. Isolation of low-Km and high-Km phosphodiesterase.  Biochim Biophys Acta. 1976;  429 485-497
• 7 Grant P G, Mannarino A F, Colman R W. Purification and characterization of a cyclic GMP-stimulated cyclic nucleotide phosphodiesterase from the cytosol of human platelets.  Thromb Res. 1990;  59 105-119
• 8 Muggli R, Tschopp T B, Mittelholzer E, Baumgartner H R. 7-Bromo-1,5-dihydro-3,6-dimethylimidazo[2,1-b]quinazolin-2(3H)-one (Ro 15-2041), a potent antithrombotic agent that selectively inhibits platelet cyclic AMP-phosphodiesterase.  J Pharmacol Exp Ther. 1985;  235 212-219
• 9 Mills D C, Smith J B. The influence on platelet aggregation of drugs that affect the accumulation of adenosine 3′:5′-cyclic monophosphate in platelets.  Biochem J. 1971;  121 185-196
• 10 Macphee C H, Harrison S A, Beavo J A. Immunological identification of the major platelet low-Km cAMP phosphodiesterase: probable target for anti-thrombotic agents.  Proc Natl Acad Sci USA. 1986;  83 6660-6663
• 11 Honerjager P. Pharmacology of bipyridine phosphodiesterase III inhibitors.  Am Heart J. 1991;  121 1939-1944
• 12 Seiler S, Gillespie E, Arnold A J, Brassard C L, Meanwell N A, Fleming J S. Imidazoquinoline derivatives: potent inhibitors of platelet cAMP phosphodiesterase which elevate cAMP levels and activate protein kinase in platelets.  Thromb Res. 1991;  62 31-42
• 13 Dawson D L, Cutler B S, Meissner M H, Strandness Jr D E. Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial.  Circulation. 1998;  98 678-686
• 14 Kambayashi J, Watase M, Kawasaki T et al.. Phosphodiesterase inhibitors as antiplatelet agents in vascular surgery.  Adv Second Messenger Phosphoprotein Res. 1992;  25 383-393
• 15 Ochiai M, Isshiki T, Takeshita S et al.. Use of cilostazol, a novel antiplatelet agent, in a post-Palmaz-Schatz stenting regimen.  Am J Cardiol. 1997;  79 1471-1474
• 16 Fitzgerald G A. Dipyridamole.  N Engl J Med. 1987;  316 1247-1257
• 17 Grant P G, Colman R W. Purification and characterization of a human platelet cyclic nucleotide phosphodiesterase.  Biochemistry. 1984;  23 1801-1807
• 18 Grant P G, Mannarino A F, Colman R W. cAMP-mediated phosphorylation of the low-Km cAMP phosphodiesterase markedly stimulates its catalytic activity.  Proc Natl Acad Sci USA. 1988;  85 9071-9075
• 19 Sheth S B, Brennan K J, Biradavolu R, Colman R W. Isolation and regulation of the cGMP-inhibited cAMP phosphodiesterase in human erythroleukemia cells.  Thromb Haemost. 1997;  77 155-162
• 20 Cheung P P, Xu H, McLaughlin M M, Ghazaleh F A, Livi G P, Colman R W. Human platelet cGI-PDE: expression in yeast and localization of the catalytic domain by deletion mutagenesis.  Blood. 1996;  88 1321-1329
• 21 Meacci E, Taira M, Moos Jr M et al.. Molecular cloning and expression of human myocardial cGMP-inhibited cAMP phosphodiesterase.  Proc Natl Acad Sci USA. 1992;  89 3721-3725
• 22 Omburo G A, Brickus T, Ghazaleh F A, Colman R W. Divalent metal cation requirement and possible classification of cGMP-inhibited phosphodiesterase as a metallohydrolase.  Arch Biochem Biophys. 1995;  323 1-5
• 23 Vallee B L, Galdes A. The metallobiochemistry of zinc enzymes.  Adv Enzymol Relat Areas Mol Biol. 1984;  56 283-430
• 24 Butt E, Beltman J, Becker D et al.. Characterization of cyclic nucleotide phosphodiesterases: topology of the catalytic domains and comparison with other cAMP-binding proteins.  Mol Pharmacol. 1995;  47 340-347
• 25 Erhardt P W. Second-generation phosphodiesterase inhibitors: structure-activity relationships and receptor models. In: Beavo J, Houslay MD Cyclic Nucleotide Phosphodiesterases: Structure, Regulation and Drug Action. New York; John Wiley & Sons 1990: 317-332
• 26 Zhang W, Ke H, Tretiakova A P, Jameson B, Colman R W. Identification of overlapping but distinct cAMP and cGMP interaction sites with cyclic nucleotide phosphodiesterase 3A by site-directed mutagenesis and molecular modeling based on crystalline PDE4B.  Protein Sci. 2001;  10 1481-1489
• 27 Grant P G, DeCamp D L, Bailey J M, Colman R W, Colman R F. Three new potential cAMP affinity labels. Inactivation of human platelet low Km cAMP phosphodiesterase by 8-[(4-bromo-2,3-dioxobutyl)thio]adenosine 3′,5′-cyclic monophosphate.  Biochemistry. 1990;  29 887-894
• 28 Taira M, Hockman S C, Calvo J C, Belfrage P, Manganiello V C. Molecular cloning of the rat adipocyte hormone-sensitive cyclic GMP-inhibited cyclic nucleotide phosphodiesterase.  J Biol Chem. 1993;  268 18573-18579
• 29 Ghazaleh F A, Omburo G A, Colman R W. Evidence for the presence of essential histidine and cysteine residues in platelet cGMP-inhibited phosphodiesterase.  Biochem J. 1996;  317 495-501
• 30 Turko I V, Francis S H, Corbin J D. Potential roles of conserved amino acids in the catalytic domain of the cAMP-binding cyclic GMP specific phosphodiesterase (PDE5).  J Biol Chem. 1998;  273 6460-6466
• 31 Cheung P P, Yu L, Zhang H, Colman R W. Partial characterization of the active site human platelet cAMP phosphodiesterase, PDE3A, by site-directed mutagenesis.  Arch Biochem Biophys. 1998;  360 99-104
• 32 Zhang W, Colman R W. Conserved amino acids in metal-binding motifs of PDE3A are involved in substrate and inhibitor binding.  Blood. 2000;  95 3380-3386
• 33 Zhang W, Ke H, Colman R W. Identification of interaction sites of cyclic nucleotide phosphodiesterase type 3A with milrinone and cilostazol using molecular modeling and site-directed mutagenesis.  Mol Pharmacol. 2002;  62 514-520
• 34 Hung S H, Madhusoodanan K S, Beres J A et al.. A new nonhydrolyzable reactive cAMP analog, (Sp)-adenosine-3′,5′-cyclic-S-(4-bromo-2,3-dioxobutyl)monophosphorothioate irreversibly inactivates human platelet cGMP-inhibited cAMP phosphodiesterase.  Bioorg Chem. 2002;  30 16-31
• 35 Hung S H, Madhusoodanan K S, Boyd R L, Baldwin J L, Colman R F, Colman R W. A nonhydrolyzable reactive cAMP analogue, (S(p))-8-[(4-bromo-2,3-dioxobutyl)thio]adenosine 3′,5′-cyclic S-(methyl)monophosphorothioate, irreversibly inactivates human platelet cGMP-inhibited cAMP phosphodiesterase at micromolar concentrations.  Biochemistry. 2002;  41 2962-2969
• 36 Omburo G A, Jacobitz S, Torphy T J, Colman R W. Critical role of conserved histidine pairs HNXXH and HDXXH in recombinant human phosphodiesterase 4A.  Cell Signal. 1998;  10 491-497
• 37 Macphee C H, Reifsnyder D H, Moore T A, Lerea K M, Beavo J A. Phosphorylation results in activation of a cAMP phosphodiesterase in human platelets.  J Biol Chem. 1988;  263 10353-10358
• 38 Podzuweit T, Nennstiel P, Muller A. Isozyme selective inhibition of cGMP-stimulated cyclic nucleotide phosphodiesterases by erythro-9-(2-hydroxy-3-nonyl) adenine.  Cell Signal. 1995;  7 733-738
• 39 Stroop S D, Charbonneau H, Beavo J A. Direct photolabeling of the cGMP-stimulated cyclic nucleotide phosphodiesterase.  J Biol Chem. 1989;  264 13718-13725
• 40 Stroop S D, Beavo J A. Structure and function studies of the cGMP-stimulated phosphodiesterase.  J Biol Chem. 1991;  266 23802-23809
• 41 Martinez S E, Wu A Y, Glavas N A et al.. The two GAF domains in phosphodiesterase 2A have distinct roles in dimerization and in cGMP binding.  Proc Natl Acad Sci USA. 2002;  99 13260-13265
• 42 Martins T J, Mumby M C, Beavo J A. Purification and characterization of a cyclic GMP-stimulated cyclic nucleotide phosphodiesterase from bovine tissues.  J Biol Chem. 1982;  257 1973-1979
• 43 Radomski M W, Palmer R M, Moncada S. The anti-aggregating properties of vascular endothelium: interactions between prostacyclin and nitric oxide.  Br J Pharmacol. 1987;  92 639-646
• 44 Maurice D H, Haslam R J. Molecular basis of the synergistic inhibition of platelet function by nitrovasodilators and activators of adenylate cyclase: inhibition of cyclic AMP breakdown by cyclic GMP.  Mol Pharmacol. 1990;  37 671-681
• 45 Manns J M, Brenna K J, Colman R W, Sheth S B. Differential regulation of human platelet responses by cGMP inhibited and stimulated cAMP phosphodiesterases.  Thromb Haemost. 2002;  87 873-879